Hisun Pharma’s Favilavir Approved to Treat Wuhan Coranovirus

Published on: February 18, 2020
Author: Amy Liu

Zhejiang Hisun Pharma reported that favilavir, a generic anti-viral, has been approved by China’s NMPA to treat COVID-19, the first approved treatment for the viral outbreak. According to unofficial reports, fapilavir showed efficacy with only minor side effects in an ongoing 70-patient clinical trial in Shenzhen, Guangdong province. The size of the trial and its “ongoing” nature imply that the approval will require further proof before it becomes permanent. Favilavir is a generic version of Fapilavir, an anti-catarrhal drug that clears mucous from the mucous membranes of the airway.

Source: China Biotoday

Biotechnology Coronavirus Healthcare Services Pharmaceutical